Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study

EoT PV-MRD enables sensitive and clinically meaningful response assessment in LBCL. It provides independent prognostic information, enhancing EoT response assessment beyond conventional radiologic assessment. Our findings support the incorporation of PV-MRD into clinical trials and routine management of diffuse LBCL.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-12-22
DOI
https://doi.org/10.1200/jco-25-01587
Citations
3
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
4.41
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study

Duane C. Hassane, Natasha H. Cutmore, Steven A. Frost, Alimu Dayimu et al.
3 citations
Journal of Clinical Oncology
Lymphoma Diagnosis and Treatment
4.41
article

Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study

Duane C. Hassane, Natasha H. Cutmore, Steven A. Frost, Alimu Dayimu, Jane Price, Aleksandra A. Kolodziejczyk, Livia Raso-Barnett, R Goodhew, Ramona-Rita Barbara, Christopher S. Trethewey, Furqaan Ahmed Kaji, Philip Barry, Ilias Moutsopoulos, Veerendra Munugalavadla, Sateesh Nagumantry, Daniel J. Hodson, Julie Smith, Silvia Tarantino, Mamatha Karanth, Nikhil Shah, Christopher P. Fox, Martin G. Thomas, Joanna A. Krupka, Kay Elston, Anver Kamil, Heok Cheow, Lee Elzubeir, Fabiana Mariscotti, Nikolaos Demiris, Shubha Anand, Matthew Ahearne
article en
3 citations

Abstract

EoT PV-MRD enables sensitive and clinically meaningful response assessment in LBCL. It provides independent prognostic information, enhancing EoT response assessment beyond conventional radiologic assessment. Our findings support the incorporation of PV-MRD into clinical trials and routine management of diffuse LBCL.

Journal of Clinical OncologyVol. 44(5)
Nottingham University Hospitals NHS Trust (GB), University of Nottingham (GB), University of Leicester (GB), Wellcome/MRC Cambridge Stem Cell Institute (GB), University of Cambridge (GB), Peterborough City Hospital (GB), Norfolk and Norwich University Hospitals NHS Foundation Trust (GB), Cancer Research UK (GB), University Hospitals of Leicester NHS Trust (GB), Cambridge University Hospitals NHS Foundation Trust (GB), Cancer Research UK Cambridge Center (GB), United Learning (GB), AstraZeneca (Australia) (AU), West Suffolk Hospital (GB), AstraZeneca (Poland) (PL), Cambridgeshire and Peterborough NHS Foundation Trust (GB), Athens University of Economics and Business (GR)
Good health and well-being
Openalex Percentile: Top 5%
Lymphoma Diagnosis and Treatment
4.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.